Drugs / Icalcaprant
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06722417 | Nov 2024 → Jan 2025 | — | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT06722430 | Nov 2024 → Jan 2025 | — | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT05547542 | Mar 2023 → Jul 2024 | substance-related disorder | Cerevel Therapeutics, LLC | Completed | No outcome recorded |
| Phase 1 | NCT05138653 | Oct 2021 → Jan 2023 | — | Cerevel Therapeutics, LLC | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06696755 | Feb 2026 → Nov 2027 expected | bipolar I disorder, bipolar II disorder | AbbVie | Recruiting | No outcome recorded |
| Phase 2 | NCT07276997 | Dec 2025 → Sep 2027 expected | major depressive disorder | AbbVie | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Icalcaprant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06722430 ↗ |
| Known as | CVL-354 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05547542 ↗ |
| Route | Oral | “oral dose of CVL-354 10 mg” NCT05138653 ↗ |